Posted On: 03/23/2014 6:04:05 PM
Post# of 63821
$HEB recovery breakout. $0.47
From 8/5/13 $0.26
10-K 3/14/14
Common Stock outstanding
March 1, 2014
was 179,340,426.
From 8/5/13 $0.26
10-K 3/14/14
Common Stock outstanding
March 1, 2014
was 179,340,426.
- Momentum Indicators for Health Care Equities -- Research on Arena Pharma, Hemispherx Biopharma, PDL BioPharma and Celgene
3/20/2014 8:16:00 AM - PR Newswire - Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference
3/19/2014 8:30:00 AM - GlobeNewswire - Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2013
3/14/2014 8:30:00 AM - GlobeNewswire - Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen(R) to Treat Chronic Fatigue Syndrome (CFS) in Three Additional Latin America Countries
3/10/2014 11:00:00 AM - GlobeNewswire - Hemispherx Biopharma Wins Federal Lawsuit Regarding Investment Banking Fees
3/10/2014 8:30:00 AM - GlobeNewswir
(0)
(0)
